Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Mei Pharma Inc (MEIP)

Mei Pharma Inc (MEIP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 347,677
  • Shares Outstanding, K 105,999
  • Annual Sales, $ 4,920 K
  • Annual Income, $ -16,820 K
  • 60-Month Beta 1.95
  • Price/Sales 59.89
  • Price/Cash Flow N/A
  • Price/Book 4.72

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate 0.13
  • Number of Estimates 3
  • High Estimate 0.66
  • Low Estimate -0.16
  • Prior Year -0.02
  • Growth Rate Est. (year over year) +750.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.19 +3.11%
on 07/06/20
4.46 -26.21%
on 06/23/20
-0.20 (-5.73%)
since 06/12/20
3-Month
2.10 +56.67%
on 04/15/20
4.46 -26.21%
on 06/23/20
+0.79 (+31.60%)
since 04/14/20
52-Week
0.72 +356.94%
on 03/19/20
4.46 -26.21%
on 06/23/20
+1.21 (+58.17%)
since 07/12/19

Most Recent Stories

More News
MEIP Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of MEI Pharma, Inc. and Encourages Investors to Contact the Firm

, /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of MEI Pharma, Inc. ("MEI Pharma" or "the Company") (NASDAQ: MEIP)....

MEIP : 3.31 (+0.91%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MEI Pharma, Inc. - MEIP

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MEI Pharma, Inc. ("MEI Pharma" or the "Company") (NASDAQ: MEIP).   Such investors are advised to contact at  or...

MEIP : 3.31 (+0.91%)
Helsinn Group and MEI Pharma Discontinue the Phase 3 Study with Pracinostat in AML after Completing Interim Analysis

Helsinn Group and MEI Pharma Discontinue the Phase 3 Study with Pracinostat in AML after Completing Interim Analysis

MEIP : 3.31 (+0.91%)
Ampio Pharmaceuticals (AMPE) Jumps: Stock Rises 8.7%

Ampio Pharmaceuticals (AMPE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

AMPE : 0.6568 (-1.74%)
MEIP : 3.31 (+0.91%)
Zogenix Gets FDA Nod for Dravet Syndrome Seizure Treatment

Zogenix (ZGNX) gets FDA nod for Fintepla oral solution, CIV for the treatment of seizures associated with Dravet Syndrome in patients 2 years of age or older.

ZGNX : 26.60 (+0.42%)
MEIP : 3.31 (+0.91%)
GWPH : 135.69 (+2.65%)
AMRX : 4.82 (-1.83%)
Zacks.com featured highlights include: YIN, CALX, OOMA and MEIP

Zacks.com featured highlights include: YIN, CALX, OOMA and MEIP

CALX : 14.30 (-1.17%)
MEIP : 3.31 (+0.91%)
YIN : 6.50 (-0.46%)
OOMA : 16.24 (+1.31%)
4 Breakout Stocks for Explosive Returns

The first step to selecting the right breakout stock is to calculate its support and resistance level.

CALX : 14.30 (-1.17%)
MEIP : 3.31 (+0.91%)
YIN : 6.50 (-0.46%)
OOMA : 16.24 (+1.31%)
Go Defensive to Beat Market Turbulence With These 4 Stocks

Opting for a defensive strategy in the current market scenario could be ideal, given that the Dow just booked its worst daily drop in more than two-and-a-half-months.

ABBV : 96.45 (-1.44%)
MEIP : 3.31 (+0.91%)
OLLI : 94.59 (+0.48%)
VST : 19.06 (-0.26%)
Is the Options Market Predicting a Spike in MEI Pharma (MEIP) Stock?

Investors need to pay close attention to MEI Pharma (MEIP) stock based on the movements in the options market lately.

MEIP : 3.31 (+0.91%)
Thinking about buying stock in Adaptimmune Therapeutics, MEI Pharma, Dynavax Technologies, AIM ImmunoTech, or Meridian Bioscience?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADAP, MEIP, DVAX, AIM, and VIVO.

ADAP : 8.97 (+0.34%)
AIM : 2.46 (-2.38%)
DVAX : 8.77 (+3.06%)
MEIP : 3.31 (+0.91%)
VIVO : 23.19 (-0.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade MEIP with:

Business Summary

MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The Company is focused on the clinical development of its two lead isoflavone-based drug candidates, ME-143 and ME-344. MEI Pharma, Inc., formerly known as Marshall Edwards,...

See More

Key Turning Points

2nd Resistance Point 3.51
1st Resistance Point 3.40
Last Price 3.31
1st Support Level 3.19
2nd Support Level 3.09

See More

52-Week High 4.46
Last Price 3.31
Fibonacci 61.8% 3.03
Fibonacci 50% 2.59
Fibonacci 38.2% 2.15
52-Week Low 0.72

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar